Back

PharmaEssentia revenue jumps 105% as Ropeg wins US and Japan ET approvals

Verifying
  • PharmaEssentia reported record August revenue and secured US and Japanese approvals for Ropeg in ET.
  • NT$2.617 billion August revenue rose 105% year-over-year and 4.38% month-over-month.
  • September 18 marks effective ETF additions after FTSE Taiwan 50 inclusion on September 4.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.